Shares of Regeneron Pharmaceuticals have plunged more than 30% over the past six months, but one Wall Street analyst believes ...

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

Regeneron Pharmaceuticals Inc.’s stock rose 4.9% Tuesday to put it on track for its biggest one-day gain in almost two years, ...

Q4 2024 Management View CEO Leonard Schleifer highlighted 10% revenue growth in Q4 2024, attributed to strong performance from Dupixent, Libtayo, and EYLEA HD. He emphasized the acceleration in EYLEA ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

Revenue rose 10% to $3.79 billion, surpassing the average $3.74 billion target from analysts polled by FactSet. Sales of the EYLEA HD more than doubled to $305 million. The medication was approved for ...

Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

LOS ANGELES, CA / ACCESS Newswire / February 5, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...

Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...

The quarter saw Regeneron grow its revenue by 10% year over year to just under $3.79 billion. Although non-GAAP (adjusted) ...

Leerink upgraded Regeneron (REGN) to Outperform from Market Perform with a price target of $834, up from $762. The shares have fallen 35% over ...